Page last updated: 2024-08-21

alpha-aminopyridine and budesonide, formoterol fumarate drug combination

alpha-aminopyridine has been researched along with budesonide, formoterol fumarate drug combination in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anzueto, A; Martinez, FJ; McIvor, A; Pizzichini, E; Rabe, KF; Rennard, SI; Sethi, S; Siddiqui, S; Zhu, H	1

Trials

1 trial(s) available for alpha-aminopyridine and budesonide, formoterol fumarate drug combination

Article	Year
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. International journal of chronic obstructive pulmonary disease, 2016, Volume: 11 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity	2016

Article

Year

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.

International journal of chronic obstructive pulmonary disease, 2016, Volume: 11

Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cyclopropanes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Research Design; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity

2016